Your browser doesn't support javascript.
loading
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Bancroft, Elizabeth K; Saya, Sibel; Page, Elizabeth C; Myhill, Kathryn; Thomas, Sarah; Pope, Jennifer; Chamberlain, Anthony; Hart, Rachel; Glover, Wayne; Cook, Jackie; Rosario, Derek J; Helfand, Brian T; Hutten Selkirk, Christina; Davidson, Rosemarie; Longmuir, Mark; Eccles, Diana M; Gadea, Neus; Brewer, Carole; Barwell, Julian; Salinas, Monica; Greenhalgh, Lynn; Tischkowitz, Marc; Henderson, Alex; Evans, David Gareth; Buys, Saundra S; Eeles, Rosalind A; Aaronson, Neil K.
Afiliação
  • Bancroft EK; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Saya S; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Page EC; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Myhill K; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Thomas S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Pope J; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Chamberlain A; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Hart R; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Glover W; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Cook J; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Rosario DJ; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Helfand BT; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Hutten Selkirk C; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
  • Davidson R; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Longmuir M; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
  • Eccles DM; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
  • Gadea N; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
  • Brewer C; Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
  • Barwell J; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
  • Salinas M; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
  • Greenhalgh L; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
  • Tischkowitz M; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
  • Henderson A; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
  • Evans DG; Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Buys SS; High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Eeles RA; Clinical Genetics, University Hospitals Leicester, Leicester, UK.
  • Aaronson NK; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain.
BJU Int ; 123(2): 284-292, 2019 02.
Article em En | MEDLINE | ID: mdl-29802810
ABSTRACT

OBJECTIVES:

To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND

METHODS:

Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following

measures:

the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented.

RESULTS:

A total of 432 men completed questionnaires 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status.

CONCLUSION:

This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Genes BRCA1 / Genes BRCA2 / Detecção Precoce de Câncer Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Genes BRCA1 / Genes BRCA2 / Detecção Precoce de Câncer Idioma: En Ano de publicação: 2019 Tipo de documento: Article